此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

2013年5月24日 更新者:Gynecologic Oncology Group

A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more tumor cells. It is not yet known whether intravenous two-drug combination chemotherapy is more effective than intravenous and intraperitoneal infusions of three-drug combination chemotherapy for treating primary peritoneal or stage III epithelial ovarian cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of intravenous two-drug combination chemotherapy with intravenous and intraperitoneal three-drug combination chemotherapy in treating patients who have primary peritoneal or stage III epithelial ovarian cancer.

研究概览

详细说明

OBJECTIVES: I. Compare pathological response, recurrence-free interval, and survival in patients with optimal stage III epithelial ovarian cancer or primary peritoneal carcinoma receiving intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel and intraperitoneal (IP) cisplatin plus IP paclitaxel. II. Compare the toxic effects and complications of these 2 treatment regimens in these patients. III. Determine the frequency and prognostic significance of BRCA1 and BRCA2 mutations in these patients. IV. Determine the effect of non-genetic risk factors on the course of disease in BRCA1- and BRCA2-related ovarian cancer or primary peritoneal carcinoma. V. Compare the quality of life of these patients receiving these treatments.

OUTLINE: This is a randomized study. Patients are stratified according to gross residual disease (present vs absent) and whether second-look surgery will be performed at the end of treatment (yes vs no). Blood is drawn for BRCA mutation analysis and DNA extraction before the start of chemotherapy, but after randomization. Patients are randomized to one of two treatment arms. Patients in arm I receive IV paclitaxel by 24-hour infusion on day 1 followed by IV cisplatin on day 2. Patients in arm II receive IV paclitaxel by 24-hour infusion on day 1 followed by intraperitoneal (IP) cisplatin on day 2, plus IP paclitaxel on day 8. Treatment for both arms repeats every 3 weeks for a total of 6 treatment courses. Following chemotherapy, second look surgery is performed if selected by the patient. Quality-of-life assessments are performed prior to randomization, prior to course 4, 3-6 weeks after the completion of course 6 and prior to second look surgery if selected, 6 months after treatment is completed, and 12 months after treatment is completed. Patients are followed every 3 months for 2 years, then every 6 months thereafter.

PROJECTED ACCRUAL: Approximately 384 patients will be accrued for this study within 16 months.

研究类型

介入性

注册 (预期的)

384

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Alberta
      • Calgary、Alberta、加拿大、T2N 4N2
        • Tom Baker Cancer Center - Calgary
    • Alabama
      • Birmingham、Alabama、美国、35294
        • University of Alabama Comprehensive Cancer Center
    • Arizona
      • Phoenix、Arizona、美国、85006-2726
        • CCOP - Greater Phoenix
    • California
      • Los Angeles、California、美国、90033-0800
        • USC/Norris Comprehensive Cancer Center
      • Los Angeles、California、美国、90095-1781
        • Jonsson Comprehensive Cancer Center, UCLA
      • Orange、California、美国、92868
        • Chao Family Comprehensive Cancer Center
      • Palo Alto、California、美国、94304
        • Women's Cancer Center
    • Colorado
      • Denver、Colorado、美国、80262
        • University of Colorado Cancer Center
    • District of Columbia
      • Washington、District of Columbia、美国、20307-5000
        • Walter Reed Army Medical Center
      • Washington、District of Columbia、美国、20007
        • Lombardi Cancer Center, Georgetown University
    • Florida
      • Tampa、Florida、美国、33612
        • H. Lee Moffitt Cancer Center and Research Institute
    • Georgia
      • Atlanta、Georgia、美国、30322
        • Emory University Hospital - Atlanta
      • Atlanta、Georgia、美国、30342-1701
        • CCOP - Atlanta Regional
    • Hawaii
      • Honolulu、Hawaii、美国、96813
        • MBCCOP - Hawaii
    • Illinois
      • Chicago、Illinois、美国、60612
        • Rush-Presbyterian-St. Luke's Medical Center
      • Chicago、Illinois、美国、60637
        • University of Chicago Cancer Research Center
      • Decatur、Illinois、美国、62526
        • CCOP - Central Illinois
      • Evanston、Illinois、美国、60201
        • CCOP - Evanston
    • Indiana
      • Indianapolis、Indiana、美国、46202-5265
        • Indiana University Cancer Center
    • Iowa
      • Iowa City、Iowa、美国、52242
        • University of Iowa Hospitals and Clinics
    • Kentucky
      • Lexington、Kentucky、美国、40536-0084
        • Albert B. Chandler Medical Center, University of Kentucky
    • Maryland
      • Baltimore、Maryland、美国、21231
        • Johns Hopkins Oncology Center
      • Bethesda、Maryland、美国、20892
        • Radiation Oncology Branch
      • Bethesda、Maryland、美国、20892
        • Medicine Branch
    • Massachusetts
      • Worcester、Massachusetts、美国、01655
        • University of Massachusetts Memorial Medical Center
    • Michigan
      • Ann Arbor、Michigan、美国、48106
        • CCOP - Ann Arbor Regional
      • Detroit、Michigan、美国、48201
        • Barbara Ann Karmanos Cancer Institute
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • University of Minnesota Cancer Center
    • Mississippi
      • Jackson、Mississippi、美国、39216-4505
        • University of Mississippi Medical Center
    • Missouri
      • Kansas City、Missouri、美国、64131
        • CCOP - Kansas City
      • Saint Louis、Missouri、美国、63110
        • Washington University School of Medicine
    • Montana
      • Billings、Montana、美国、59101
        • CCOP - Montana Cancer Consortium
    • Nebraska
      • Omaha、Nebraska、美国、68131
        • CCOP - Missouri Valley Cancer Consortium
    • Nevada
      • Las Vegas、Nevada、美国、89106
        • CCOP - Southern Nevada Cancer Research Foundation
    • New Jersey
      • Camden、New Jersey、美国、08103
        • Cooper Hospital/University Medical Center
      • Livingston、New Jersey、美国、07039
        • St. Barnabas Medical Center
      • Morristown、New Jersey、美国、07962-1956
        • Morristown Memorial Hospital
    • New York
      • Albany、New York、美国、12208
        • Cancer Center of Albany Medical Center
      • Brooklyn、New York、美国、11203
        • State University of New York Health Science Center at Brooklyn
      • Manhasset、New York、美国、11030
        • North Shore University Hospital
      • New York、New York、美国、10021
        • Memorial Sloan-Kettering Cancer Center
      • Rochester、New York、美国、14642
        • University of Rochester Cancer Center
      • Stony Brook、New York、美国、11790-7775
        • State University of New York Health Sciences Center - Stony Brook
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599-7295
        • Lineberger Comprehensive Cancer Center, UNC
      • Durham、North Carolina、美国、27710
        • Duke Comprehensive Cancer Center
      • Winston-Salem、North Carolina、美国、27157-1082
        • Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
    • Ohio
      • Cincinnati、Ohio、美国、45219
        • Barrett Cancer Center, The University Hospital
      • Cleveland、Ohio、美国、44195
        • Cleveland Clinic Cancer Center
      • Cleveland、Ohio、美国、44106-5065
        • Ireland Cancer Center
      • Columbus、Ohio、美国、43210
        • Arthur G. James Cancer Hospital - Ohio State University
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73190
        • University of Oklahoma College of Medicine
      • Tulsa、Oklahoma、美国、74136
        • CCOP - Sooner State
    • Oregon
      • Portland、Oregon、美国、97213
        • CCOP - Columbia River Program
    • Pennsylvania
      • Abington、Pennsylvania、美国、19001
        • Abington Memorial Hospital
      • Hershey、Pennsylvania、美国、17033
        • Milton S. Hershey Medical Center
      • Philadelphia、Pennsylvania、美国、19111
        • Fox Chase Cancer Center
      • Philadelphia、Pennsylvania、美国、19104
        • University of Pennsylvania Cancer Center
      • Philadelphia、Pennsylvania、美国、19107
        • Kimmel Cancer Center of Thomas Jefferson University - Philadelphia
    • South Carolina
      • Charleston、South Carolina、美国、29425-0721
        • Medical University of South Carolina
      • Spartanburg、South Carolina、美国、29303
        • CCOP - Upstate Carolina
    • Tennessee
      • Memphis、Tennessee、美国、38117
        • CCOP - Baptist Cancer Institute
      • Nashville、Tennessee、美国、37203
        • Brookview Research, Inc.
    • Texas
      • Dallas、Texas、美国、75235-9154
        • Simmons Cancer Center - Dallas
      • Houston、Texas、美国、77030
        • University of Texas - MD Anderson Cancer Center
    • Virginia
      • Charlottesville、Virginia、美国、22908
        • Cancer Center, University of Virginia HSC
    • Washington
      • Seattle、Washington、美国、98195-6043
        • University of Washington Medical Center
      • Tacoma、Washington、美国、98405
        • Tacoma General Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

有资格学习的性别

女性

描述

DISEASE CHARACTERISTICS: Histologically proven primary peritoneal carcinoma or optimal (no greater than 1 cm residual disease) stage III epithelial ovarian carcinoma with the following epithelial cell types: Serous adenocarcinoma Endometrioid adenocarcinoma Mucinous adenocarcinoma Undifferentiated carcinoma Clear cell adenocarcinoma Mixed epithelial carcinoma Transitional cell carcinoma Malignant Brenner's Tumor Adenocarcinoma NOS Prior surgery for ovarian/peritoneal carcinoma required No epithelial ovarian carcinoma of low malignant potential (borderline carcinoma)

PATIENT CHARACTERISTICS: Age: Not specified Performance status: GOG 0-2 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 times normal SGOT no greater than 3 times normal Alkaline phosphatase no greater than 3 times normal No acute hepatitis Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No unstable angina No myocardial infarction within prior 6 months Patients with abnormal cardiac conduction are eligible if disease stable for at least 6 months Other: No septicemia or severe infection No severe gastrointestinal bleeding No other invasive malignancy within past 5 years except nonmelanoma skin cancer Any previous cancer treatment must not contraindicate this protocol therapy

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy Surgery: See Disease Characteristics No more than 6 weeks since prior surgery

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

1998年3月1日

初级完成 (实际的)

2006年1月1日

研究注册日期

首次提交

1999年11月1日

首先提交符合 QC 标准的

2004年5月20日

首次发布 (估计)

2004年5月21日

研究记录更新

最后更新发布 (估计)

2013年5月27日

上次提交的符合 QC 标准的更新

2013年5月24日

最后验证

2012年8月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅